Vnitr Lek 2015, 61(6):537-546

Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban

Jan Kvasnička1,*, Miroslav Penka2, Tomáš Kvasnička1, Jana Michalcová2, Zuzana Kudrnová1, Ivana Malíková1
1 Trombotické centrum Ústavu klinické biochemie a laboratorní diagnostiky 1. LF UK a VFN Praha, přednosta prof. MUDr. Tomáš Zima, DrSc., MBA
2 Oddělení klinické hematologie FN Brno, primář prof. MUDr. Miroslav Penka, CSc.

There are presently new oral anticoagulants (NOAC) for prevention and the treatment of thromboembolic diseases and they are registered in CZ. It concerns of orally direct inhibitors of thrombin (dabigatran etexilate), inhibitors of factor Xa (apixaban, rivaroxaban), respectively, with advantage of some properties not being seen in "classical" anticoagulants. In the use of new anticoagulants, however, are some problems - such as laboratory monitoring in urgent situations of effective treatment and the absence of specific antidote - resolved. The text below brings indications, dosage of the drugs, their elimination, follow-up of efficacy of the treatment or risk of the bleeding as well as the therapy of bleeding complications.

Keywords: apixaban; dabigatran etexilate; NOAC; rivaroxaban

Received: June 3, 2015; Published: June 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvasnička J, Penka M, Kvasnička T, Michalcová J, Kudrnová Z, Malíková I. Guidelines of Czech Association for Thrombosis and Haemostasis of the Czech Medical Association of J. E. Purkyně for safety treatment with new oral anticoagulants (NOAC) - dabigatran etexilate, apixaban and rivaroxaban. Vnitr Lek. 2015;61(6):537-546.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The European Medicines Agency. Souhrn údajů o přípravku Pradaxa. [online]. Dostupné z WWW: <http://www.emea.europa.eu/docs/cs_CZ/document_librar y/EPAR _-_Product_Information/human/000829/WC500041059.pdf>.
    2. The European Medicines Agency. Souhrn údajů o přípravku Xarelto. [online]. Dostupné z WWW: <http://www.emea.europa.eu/docs/cs_CZ/document_librar y/EPAR _-_Product_Information/human/000944/WC500057108.pdf>.
    3. The European Medicines Agency. Souhrn údajů o přípravku Eliquis. [online]. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf>.
    4. Čihák R, Haman L, Táborský M. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa 56(2014) e42-e56. Dostupné z WWW: <http://www.sciencedirect.com/science/article/pii/S001086501300129X>. Go to original source...
    5. Čihák R, Haman L, Heinc P. Souhrn Aktualizace doporučených postupů ESC pro léčbu fibrilace síní z roku 2012. Cor Vasa 2012; 54: e341-e351. Dostupné z WWW: <http://www.sciencedirect.com/science/article/pii/S0010865012001257?v=s5>. Go to original source...
    6. Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651. Dostupné z DOI: <http://doi:10.1093/europace/eut083>. Go to original source... Go to PubMed...
    7. Penka M, Penka I, Gumulec J et al. Krvácení. Grada Publishing: Praha 2014. ISBN 978-80-247-0689-4.
    8. Baglin T, Hillarp A, Tripodi A et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11(Suppl 2): 765-760. Go to original source... Go to PubMed...
    9. Kvasnička J, Malíková I. Nová perorální přímá antikoagulancia (NOAC) - jak řešit možné problémy s vyšetřením koagulace. Anest Intenziv Med 2014; 25(5): 367-372.
    10. Tsakiris DA, Alberio LA et al. Quantifizierung von Rivaroxaban und Beeinflussung von Gerinnungstests bei Patienten mit Rivaroxaban (Xarelto®) [online]. 2012. Dostupné z WWW: <http://www.sgh-ssh.ch/upload/File/2012_11.10._Rivaroxaban_D.pdf>.
    11. Kozek-Langenecker SA, Afshari A, Albaladejo P et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30(6): 270-382. Go to original source... Go to PubMed...
    12. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013; 34(7): 489-498b. Go to original source... Go to PubMed...
    13. Khadyzhynov D, Wagner F, Formella S et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013; 109(4): 596-605. Go to original source... Go to PubMed...
    14. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol 2015; 35(5): 1056-1065. Go to original source... Go to PubMed...
    15. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost 2015; 113(5): 931-942. Go to original source... Go to PubMed...
    16. Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ 2014; 349: g4606. Dostupné z DOI: <http://doi:10.1136/bmj.g4606>. Go to original source... Go to PubMed...
    17. Ageno W, Crowther M, Baglin T et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11(1): 177-179. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.